Long Hai-bo, Niu Hong-xin, Li Xiao-yun, Xu Zhao-zhong, Zhang Hui, Zhong Juan, Wei Lian-bo
Nephropathy Center of Integrated Traditional Chinese Medicine and Western Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2010 Apr;30(4):805-9.
To investigate the effects of Shenkangwan on the expressions of angiotensin II (AngII) and its type I receptor (AT(1)R) and the renalprotection mechanism of Shenkangwan in rats with early diabetic nephropathy (DN).
The rat models of DN established by a single injection of streptozotocin were randomly divided into 4 groups, namely the model group, Shenkangwan treatment group, irbesartan treatment group, and Shenkangwan and irbesartan treatment group, with normal rats as the control. All the rats received daily gavage for 8 weeks. The urinary protein quality in 24 h and plasma and renal contents of AngII were measured. The expressions of AT1R at the protein and mRNA levels in the kidney tissues were measured by immunohistochemistry and reverse transcription-polymerase chain reaction, respectively. The pathological changes of the kidney were observed microscopically.
In DN rats, Shenkangwan reduced the urinary protein quantity in 24 h and the contents of AngII in the plasma and kidney tissues, decreased the renal expressions of AT(1)R protein and mRNA, and alleviated the morphological damage of the kidney.
Shenkangwan offers renalprotection against DN probably by reducing the contents of AngII in the plasma and kidney tissues and inhibiting renal AT(1)R expressions.
探讨肾康丸对早期糖尿病肾病（DN）大鼠血管紧张素II（AngII）及其1型受体（AT(1)R）表达的影响以及肾康丸的肾脏保护机制。
将单次注射链脲佐菌素建立的DN大鼠模型随机分为4组，即模型组、肾康丸治疗组、厄贝沙坦治疗组、肾康丸与厄贝沙坦联合治疗组，以正常大鼠作为对照。所有大鼠每日灌胃给药8周。测定24小时尿蛋白量以及血浆和肾脏中AngII的含量。分别采用免疫组织化学法和逆转录-聚合酶链反应法检测肾组织中AT1R蛋白和mRNA水平的表达。显微镜下观察肾脏的病理变化。
在DN大鼠中，肾康丸降低了24小时尿蛋白量以及血浆和肾脏组织中AngII的含量，减少了肾脏AT(1)R蛋白和mRNA的表达，并减轻了肾脏的形态学损伤。
肾康丸可能通过降低血浆和肾脏组织中AngII的含量以及抑制肾脏AT(1)R的表达而对DN起到肾脏保护作用。
